Research ArticleDrug Discovery and Translational Medicine
Open Access
Utilizing Designed Receptors Exclusively Activated by Designer Drug Chemogenetic Tools to Identify Beneficial G Protein–Coupled Receptor Signaling for Fibrosis
Ji Zhang, Eyal Vardy, Eric S. Muise, Tzu-Ming Wang, Richard Visconti, Ashita Vadlamudi, Shirly Pinto and Andrea M. Peier
Journal of Pharmacology and Experimental Therapeutics November 2020, 375 (2) 357-366; DOI: https://doi.org/10.1124/jpet.120.000103
Ji Zhang
Departments of Cardiometabolic Diseases (J.Z., S.P.), Screening and Compound Profiling (E.V., R.V., A.V., A.M.P.), GpGx (E.S.M.), and Translational Biomarkers (T.-M.W.), MRL, Merck & Co., Inc., Kenilworth, New Jersey; and Kallyope Inc., New York, New York (E.V., S.P.)
Eyal Vardy
Departments of Cardiometabolic Diseases (J.Z., S.P.), Screening and Compound Profiling (E.V., R.V., A.V., A.M.P.), GpGx (E.S.M.), and Translational Biomarkers (T.-M.W.), MRL, Merck & Co., Inc., Kenilworth, New Jersey; and Kallyope Inc., New York, New York (E.V., S.P.)
Eric S. Muise
Departments of Cardiometabolic Diseases (J.Z., S.P.), Screening and Compound Profiling (E.V., R.V., A.V., A.M.P.), GpGx (E.S.M.), and Translational Biomarkers (T.-M.W.), MRL, Merck & Co., Inc., Kenilworth, New Jersey; and Kallyope Inc., New York, New York (E.V., S.P.)
Tzu-Ming Wang
Departments of Cardiometabolic Diseases (J.Z., S.P.), Screening and Compound Profiling (E.V., R.V., A.V., A.M.P.), GpGx (E.S.M.), and Translational Biomarkers (T.-M.W.), MRL, Merck & Co., Inc., Kenilworth, New Jersey; and Kallyope Inc., New York, New York (E.V., S.P.)
Richard Visconti
Departments of Cardiometabolic Diseases (J.Z., S.P.), Screening and Compound Profiling (E.V., R.V., A.V., A.M.P.), GpGx (E.S.M.), and Translational Biomarkers (T.-M.W.), MRL, Merck & Co., Inc., Kenilworth, New Jersey; and Kallyope Inc., New York, New York (E.V., S.P.)
Ashita Vadlamudi
Departments of Cardiometabolic Diseases (J.Z., S.P.), Screening and Compound Profiling (E.V., R.V., A.V., A.M.P.), GpGx (E.S.M.), and Translational Biomarkers (T.-M.W.), MRL, Merck & Co., Inc., Kenilworth, New Jersey; and Kallyope Inc., New York, New York (E.V., S.P.)
Shirly Pinto
Departments of Cardiometabolic Diseases (J.Z., S.P.), Screening and Compound Profiling (E.V., R.V., A.V., A.M.P.), GpGx (E.S.M.), and Translational Biomarkers (T.-M.W.), MRL, Merck & Co., Inc., Kenilworth, New Jersey; and Kallyope Inc., New York, New York (E.V., S.P.)
Andrea M. Peier
Departments of Cardiometabolic Diseases (J.Z., S.P.), Screening and Compound Profiling (E.V., R.V., A.V., A.M.P.), GpGx (E.S.M.), and Translational Biomarkers (T.-M.W.), MRL, Merck & Co., Inc., Kenilworth, New Jersey; and Kallyope Inc., New York, New York (E.V., S.P.)
Submit a Response to This Article
Jump to comment:
No eLetters have been published for this article.
In this issue
Research ArticleDrug Discovery and Translational Medicine
GPCR Signaling in Fibrosis
Ji Zhang, Eyal Vardy, Eric S. Muise, Tzu-Ming Wang, Richard Visconti, Ashita Vadlamudi, Shirly Pinto and Andrea M. Peier
Journal of Pharmacology and Experimental Therapeutics November 1, 2020, 375 (2) 357-366; DOI: https://doi.org/10.1124/jpet.120.000103
Research ArticleDrug Discovery and Translational Medicine
GPCR Signaling in Fibrosis
Ji Zhang, Eyal Vardy, Eric S. Muise, Tzu-Ming Wang, Richard Visconti, Ashita Vadlamudi, Shirly Pinto and Andrea M. Peier
Journal of Pharmacology and Experimental Therapeutics November 1, 2020, 375 (2) 357-366; DOI: https://doi.org/10.1124/jpet.120.000103
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement